Leucémie myéloïde en phase accélérée : Questions médicales fréquentes
Nom anglais: Leukemia, Myeloid, Accelerated Phase
Descriptor UI:D015465
Tree Number:C23.550.291.500.485.300
Termes MeSH sélectionnés :
Time and Motion Studies
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Leucémie myéloïde en phase accélérée : Questions médicales les plus fréquentes",
"headline": "Leucémie myéloïde en phase accélérée : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Leucémie myéloïde en phase accélérée : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-30",
"dateModified": "2025-02-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Leucémie myéloïde en phase accélérée"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Leucémie myéloïde chronique BCR-ABL positive",
"url": "https://questionsmedicales.fr/mesh/D015464",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie myéloïde chronique BCR-ABL positive",
"code": {
"@type": "MedicalCode",
"code": "D015464",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.291.500.485"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Leucémie myéloïde en phase accélérée",
"alternateName": "Leukemia, Myeloid, Accelerated Phase",
"code": {
"@type": "MedicalCode",
"code": "D015465",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elias Jabbour",
"url": "https://questionsmedicales.fr/author/Elias%20Jabbour",
"affiliation": {
"@type": "Organization",
"name": "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."
}
},
{
"@type": "Person",
"name": "Gautam Borthakur",
"url": "https://questionsmedicales.fr/author/Gautam%20Borthakur",
"affiliation": {
"@type": "Organization",
"name": "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."
}
},
{
"@type": "Person",
"name": "Farhad Ravandi",
"url": "https://questionsmedicales.fr/author/Farhad%20Ravandi",
"affiliation": {
"@type": "Organization",
"name": "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."
}
},
{
"@type": "Person",
"name": "Jorge E Cortes",
"url": "https://questionsmedicales.fr/author/Jorge%20E%20Cortes",
"affiliation": {
"@type": "Organization",
"name": "Georgia Cancer Center, Augusta, Georgia, USA."
}
},
{
"@type": "Person",
"name": "Hagop Kantarjian",
"url": "https://questionsmedicales.fr/author/Hagop%20Kantarjian",
"affiliation": {
"@type": "Organization",
"name": "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Timing of Switching to Steroid Implants in Cases of Recalcitrant Diabetic Macular Edema Not Responding to Anti-vascular Endothelial Growth Factor (VEGF) Therapy: A Real-World Study.",
"datePublished": "2024-06-14",
"url": "https://questionsmedicales.fr/article/39006597",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7759/cureus.62385"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bone alteration and esthetics associated with implant-supported prostheses in the anterior maxilla under different implant placement timing: A retrospective clinical study of 1 to 3 years.",
"datePublished": "2024-05-28",
"url": "https://questionsmedicales.fr/article/38806340",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.prosdent.2024.04.032"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of Changes in the Outcome of Autogenous Tooth Grafts Over Time: A Clinical Study Evaluating Periodontal Healing in Bone Defects After Lower Third Molar Removal.",
"datePublished": "2024-05-22",
"url": "https://questionsmedicales.fr/article/38851213",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.joms.2024.05.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Quantification of the Heat-Related Risk and Burden of Hospitalizations for Cause-Specific Injuries and Contribution of Human-Induced Climate Change: A Time-Stratified Case-Crossover Study in China.",
"datePublished": "2024-05-16",
"url": "https://questionsmedicales.fr/article/38752990",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1289/EHP14057"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bayesian estimation of the time-varying reproduction number for pulmonary tuberculosis in Iran: A registry-based study from 2018 to 2022 using new smear-positive cases.",
"datePublished": "2024-05-10",
"url": "https://questionsmedicales.fr/article/38873589",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.idm.2024.05.003"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Processus pathologiques",
"item": "https://questionsmedicales.fr/mesh/D010335"
},
{
"@type": "ListItem",
"position": 4,
"name": "Caractéristiques de la maladie",
"item": "https://questionsmedicales.fr/mesh/D020969"
},
{
"@type": "ListItem",
"position": 5,
"name": "Maladie chronique",
"item": "https://questionsmedicales.fr/mesh/D002908"
},
{
"@type": "ListItem",
"position": 6,
"name": "Leucémie myéloïde chronique BCR-ABL positive",
"item": "https://questionsmedicales.fr/mesh/D015464"
},
{
"@type": "ListItem",
"position": 7,
"name": "Leucémie myéloïde en phase accélérée",
"item": "https://questionsmedicales.fr/mesh/D015465"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Leucémie myéloïde en phase accélérée - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Leucémie myéloïde en phase accélérée",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Leucémie myéloïde en phase accélérée",
"description": "Comment diagnostiquer la leucémie myéloïde en phase accélérée ?\nQuels tests sont utilisés pour confirmer le diagnostic ?\nQuels signes indiquent une phase accélérée ?\nQuelle est l'importance de la biopsie de moelle osseuse ?\nPeut-on utiliser l'imagerie pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D015465?mesh_terms=Time+and+Motion+Studies&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Leucémie myéloïde en phase accélérée",
"description": "Quels sont les symptômes courants de cette leucémie ?\nComment la leucémie affecte-t-elle le système immunitaire ?\nY a-t-il des symptômes spécifiques à la phase accélérée ?\nLes symptômes varient-ils d'un patient à l'autre ?\nComment la leucémie myéloïde affecte-t-elle la santé globale ?",
"url": "https://questionsmedicales.fr/mesh/D015465?mesh_terms=Time+and+Motion+Studies&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Leucémie myéloïde en phase accélérée",
"description": "Peut-on prévenir la leucémie myéloïde en phase accélérée ?\nQuels facteurs de risque sont évitables ?\nLe mode de vie influence-t-il le risque ?\nLes examens réguliers aident-ils à la prévention ?\nY a-t-il des vaccins pour prévenir la leucémie ?",
"url": "https://questionsmedicales.fr/mesh/D015465?mesh_terms=Time+and+Motion+Studies&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Leucémie myéloïde en phase accélérée",
"description": "Quels traitements sont disponibles pour cette leucémie ?\nLa chimiothérapie est-elle efficace en phase accélérée ?\nQuelles thérapies ciblées sont utilisées ?\nQuand envisager une greffe de moelle osseuse ?\nQuels sont les effets secondaires des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D015465?mesh_terms=Time+and+Motion+Studies&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Leucémie myéloïde en phase accélérée",
"description": "Quelles complications peuvent survenir ?\nComment les infections sont-elles gérées ?\nLa leucémie peut-elle entraîner des problèmes cardiaques ?\nQuels sont les risques de saignement ?\nComment prévenir les complications ?",
"url": "https://questionsmedicales.fr/mesh/D015465?mesh_terms=Time+and+Motion+Studies&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Leucémie myéloïde en phase accélérée",
"description": "Quels sont les principaux facteurs de risque ?\nLe tabagisme est-il un facteur de risque ?\nLes maladies génétiques augmentent-elles le risque ?\nL'âge est-il un facteur de risque ?\nLes traitements antérieurs contre le cancer influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D015465?mesh_terms=Time+and+Motion+Studies&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la leucémie myéloïde en phase accélérée ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des analyses sanguines, une biopsie de moelle osseuse et des tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests cytogénétiques et la PCR pour détecter des mutations spécifiques sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une phase accélérée ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation rapide des blastes dans le sang et des symptômes cliniques aggravés."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la biopsie de moelle osseuse ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet d'évaluer la proportion de cellules leucémiques et d'étudier leur morphologie."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas couramment utilisée, mais peut aider à évaluer des complications."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de cette leucémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, fièvre, infections fréquentes, ecchymoses et saignements anormaux."
}
},
{
"@type": "Question",
"name": "Comment la leucémie affecte-t-elle le système immunitaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle diminue la production de globules blancs fonctionnels, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à la phase accélérée ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes plus graves comme des douleurs osseuses et une splénomégalie peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'un patient à l'autre ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la combinaison des symptômes peuvent varier selon les individus."
}
},
{
"@type": "Question",
"name": "Comment la leucémie myéloïde affecte-t-elle la santé globale ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner une dégradation rapide de l'état général et des complications graves."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la leucémie myéloïde en phase accélérée ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont évitables ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'exposition à des produits chimiques toxiques et réduire le tabagisme peut aider."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque de certaines maladies, mais pas spécifiquement la leucémie."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers peuvent aider à détecter des anomalies précoces, mais ne préviennent pas la maladie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir la leucémie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de vaccins spécifiques pour prévenir la leucémie myéloïde."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour cette leucémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, les thérapies ciblées et la greffe de moelle."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace en phase accélérée ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut réduire rapidement le nombre de cellules leucémiques, mais les résultats varient."
}
},
{
"@type": "Question",
"name": "Quelles thérapies ciblées sont utilisées ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de tyrosine kinase comme l'imatinib peuvent être utilisés selon les mutations."
}
},
{
"@type": "Question",
"name": "Quand envisager une greffe de moelle osseuse ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La greffe est envisagée si la maladie ne répond pas aux traitements ou en cas de rechute."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure nausées, fatigue, infections et anémie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections graves, des saignements et des défaillances organiques."
}
},
{
"@type": "Question",
"name": "Comment les infections sont-elles gérées ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections sont traitées rapidement avec des antibiotiques et des soins intensifs si nécessaire."
}
},
{
"@type": "Question",
"name": "La leucémie peut-elle entraîner des problèmes cardiaques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements et la maladie elle-même peuvent augmenter le risque de complications cardiaques."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de saignement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients peuvent avoir des saignements spontanés en raison de la thrombopénie associée."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et une gestion proactive des symptômes peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition à des radiations, des produits chimiques et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à un risque accru de développer des leucémies."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques, comme le syndrome de Down, augmentent le risque de leucémie."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de leucémie myéloïde augmente avec l'âge, surtout après 60 ans."
}
},
{
"@type": "Question",
"name": "Les traitements antérieurs contre le cancer influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements antérieurs, comme la chimiothérapie, peuvent augmenter le risque de leucémie."
}
}
]
}
]
}
Purpose The purpose of this study is to examine the impact of the timing of the steroid switch on both visual and anatomical outcomes in diabetic macular edema (DME) eyes that have shown an inadequate...
Different factors influence alterations in facial bone thickness and esthetic outcomes after implant placement. Whether the timing of implant placement influences alterations in the bone dimensional a...
The purpose of this retrospective clinical study was to assess the influence of the timing of implant placement on alveolar bone alterations and esthetic outcome....
Data were collected from 40 patients who had received guided bone regeneration (GBR) performed simultaneously with immediate, early, or delayed single-tooth implant placement in the anterior maxilla. ...
The reduction in the FHBT...
Similar bone changes and esthetic outcomes were found around implants of the immediate, early, and delayed implant placement groups....
The removal of impacted lower third molars (ILTMs) is associated with bone defects in the distal area of second molars. Different methods have been described to minimize these defects....
The primary objective was to assess changes in probing depth (PD) over time (up to 36 months) between test (grafted) and control (ungrafted) groups; the graft was obtained from the extracted ILTM....
This split-mouth randomized clinical trial was conducted at the Postgraduate Course in Oral Surgery of the Faculty of Dentistry of the Complutense University of Madrid. Adult patients requiring bilate...
The predictor variable was the graft technique. The bone defect after ILTM removal was treated with autogenous tooth graft (ATG) in the test group, leaving the control group ungrafted....
PD on the distobuccal, distomedial, and distolingual surfaces was recorded in both groups and averaged at baseline (T0), 3 (T1), 6 (T2), and 36 months (T3) postoperatively....
Sex, age, surgical time, ILTM situation and position between groups were assessed....
ANOVA repeated measures for comparisons between groups and the Friedman test for comparisons within the groups over time were applied. Statistical significance was established with a confidence interv...
The sample comprised 22 patients (6 males, 16 females) with a mean age of 21.68 ± 2.19 years; 44 ILTM extractions were performed. Statistically significant differences in PD average were found between...
ATG placed on the distal surface of lower second molars and almost completely filling the extraction socket improved PD 3, 6 and 36 months after ILTM. Furthermore, no significant changes in PD were ob...
Although ambient temperature has been linked with injury incidence, there have been few nationwide studies to quantify the temperature-related risk and burden of cause-specific injury hospitalizations...
Our objectives are to examine the associations between ambient temperature and injury hospitalizations from various causes and to quantify the contribution of human-induced warming to the heat-related...
We collected injury hospitalization data from a nationwide hospital-based registry in China during 2000-2019. Using a time-stratified case-crossover design, we investigated the associations between da...
Our study included a total of 988,087 patients with hospitalization records for injuries. Overall, compared to the temperature at minimum risk of hospitalization (...
This nationwide study presents new evidence of significant associations between temperature and cause-specific injury hospitalizations in China and highlights the increasing contribution of human-indu...
Tuberculosis (TB) is one of the most prevalent infectious diseases in the world, causing major public health problems in developing countries. The rate of TB incidence in Iran was estimated to be 13 p...
The present national historical cohort study was conducted from March 2018 to March 2022 based on data from the National Tuberculosis and Leprosy Registration Center of Iran's Ministry of Health and M...
The mean age at diagnosis of patients was 52.3 ± 21.2 years, and most patients were in the 35-63 age group (37.1%). Among the data, 9121 (56.4%) cases were males, and 7044 (43.6%) were females. Among ...
In this study, the incidence and the time-varying reproduction number of pulmonary tuberculosis showed the same pattern. The mean of the time-varying reproduction number indicated that each infected p...
To prospectively investigate the associations of longitudinal changes in sleep score and LTPA and their combination with all-cause mortality....
Among 12,543 participants (mean age: 66.1 years) from the Dongfeng-Tongji cohort, we calculated sleep score (range, 0-4, integrating bedtime, sleep duration, sleep quality, and midday napping, higher ...
During a mean 5.5-year follow-up, 792 deaths occurred. The 5-year changes in sleep score and LTPA were inversely associated with all-cause mortality risk, regardless of their initial values. When asse...
Promoting sleep hygiene and LTPA together may benefit efforts in reducing mortality risk, with particular attention to monitoring long-term sleep health....
This study evaluated the effect of Momentum-an integrated family planning, maternal and newborn health, and nutrition intervention-on postpartum family planning norms and behaviors among ever married ...
Bone staples have been shown previously to be a viable modality for cortical tendon graft fixation in ligament knee surgery. However, soft tissue reactions have been reported, making implant removal n...
To compare the primary stability of a biodegradable bone staple prototype made from magnesium to bone staples made from metal in the cortical fixation of tendon grafts during knee surgery....
Controlled laboratory study....
Primary stability of peripheral tendon graft fixation was assessed in a porcine model of medial collateral ligament reconstruction. Two commercially available metal bone staples (Richards fixation sta...
After 500 cycles at 50 N, elongation was 1.5 ± 0.5 mm in the Me1 group, 1.9 ± 0.5 mm in the Me2 group, and 1.8 ± 0.4 mm in the magnesium group. After 1000 cycles of loading (500 cycles at 50 N and 500...
In this study, the magnesium bone staples provided appropriate time-zero biomechanical primary stability in comparison with metal bone staples and may therefore be a feasible alternative for cortical ...
The biodegradability of magnesium bone staples would eliminate the need for later implant removal....
Clinical decision support systems (CDSSs) embedded in electronic medical records (EMRs), also called electronic health records, have the potential to improve the adoption of clinical guidelines. The U...
This study aims to evaluate the impact of the IBD CDSS on the adherence of health care providers (ie, physicians and nurses) to institutionally agreed clinical management protocols....
A 2-period interrupted time series (ITS) design, comparing adherence to a clinical flare management protocol during outpatient visits before and after the CDSS implementation, was used. Each interrupt...
Following manual screening, 623 flare encounters were confirmed and designated for ITS analysis. The CDSS was activated in 198 of 623 encounters, most commonly in cases where the primary visit reason ...
This is one of the first studies to investigate the implementation of a CDSS for IBD, designed with a leading EMR software (Epic Systems), providing initial evidence of an improvement over routine car...
Opioids have traditionally been used to manage acute or terminal pain. However, their prolonged use has the potential for abuse, misuse, and addiction. South Korea introduced a new health care IT syst...
This study aimed to assess the impact of NIMS on opioid use....
We conducted an analysis using national claims data from 45,582 patients diagnosed with musculoskeletal and connective tissue disorders between 2016 and 2020. Our approach included using an interrupte...
During the study period, there was a general trend of increasing opioid use. After the implementation of NIMS, significant increases were observed in the trend of the proportion of patients on high-do...
This study suggests that, in its current form, the NIMS may not have brought significant improvements to the identified indicators of opioid overuse and misuse. Additionally, the COVID-19 outbreak exh...